Vanda Pharmaceuticals Inc.
VNDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001347178
No open-market purchases or sales by Vanda Pharmaceuticals Inc. insiders were filed in the last 90 days; 172 institutions reported holding it in 13F filings for Q2 2026, worth $304.1M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Vanda Pharmaceuticals Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 157 | 144 | −13 |
| Shares | 50.7M | 48.2M | −2.54M (−5.0%) |
| Value | $213.8M | $198.0M | −$15.8M (−7.4%) |
New holders (19)
Institutions that held Vanda Pharmaceuticals Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Wellington Management Group LLP | 435,767 | $1.79M | 0.00% |
| Susquehanna Fundamental Investments, LLC | 281,683 | $1.16M | 0.05% |
| Empire Financial Management Company, LLC | 65,000 | $267.1K | 0.09% |
| Occudo Quantitative Strategies LP | 57,769 | $237.4K | 0.04% |
| Man Group plc | 47,730 | $196.2K | 0.00% |
| Virtu Financial LLC | 46,969 | $193.0K | 0.01% |
| Sherbrooke Park Advisers LLC | 39,229 | $161.2K | 0.03% |
| Schulhoff & Co Inc | 38,500 | $158.2K | 0.07% |
| Engineers Gate Manager LP | 19,345 | $79.5K | 0.00% |
| Point72 (DIFC) Ltd | 16,301 | $67.0K | 0.01% |
| Savant Capital, LLC | 15,094 | $62.0K | 0.00% |
| Aigen Investment Management, LP | 11,597 | $47.7K | 0.01% |
| Quantbot Technologies LP | 7,300 | $30.0K | 0.00% |
| Aquatic Capital Management LLC | 300 | $1.23K | 0.00% |
| Parallel Advisors, LLC | 87 | $358 | 0.00% |
| GPS Wealth Strategies Group, LLC | 25 | $103 | 0.00% |
| Catalyst Funds Management Pty Ltd | 22 | $90 | 0.00% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 10 | $41 | 0.00% |
| SageView Advisory Group, LLC | 8,249 | – | – |
Sold out (32)
Institutions that held Vanda Pharmaceuticals Inc. at the end of Q4 2023 and filed for Q1 2024 without it.